Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

EQ

Equillium Inc

Dec 06 • 04:00PM ET

0.7336

Dollar change +0.0536
Percentage change 7.88	%

Healthcare • Biotechnology • USA • NASD

Peers: ATRA LGND CLDX FATE ANAB ADMA BDTX KNSA CRBP CYCN

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.13	Insider Own	50.82%	Shs Outstand	35.42M	Perf Week	-2.32%
Market Cap	28.04M	Forward P/E	-	EPS next Y	-1.12	Insider Trans	-0.48%	Shs Float	17.43M	Perf Month	-2.37%
Income	-4.62M	PEG	-	EPS next Q	-0.32	Inst Own	5.32%	Short Float	0.88%	Perf Quarter	-17.98%
Sales	45.91M	P/S	0.61	EPS this Y	-31.58%	Inst Trans	-6.49%	Short Ratio	0.90	Perf Half Y	-8.41%
Book/sh	0.65	P/B	1.12	EPS next Y	-123.33%	ROA	-10.29%	Short Interest	0.15M	Perf Year	20.86%
Cash/sh	0.68	P/C	1.08	EPS next 5Y	-	ROE	-19.52%	52W Range	0.49 - 3.25	Perf YTD	1.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.79%	ROI	-19.72%	52W High	-77.43%	Beta	1.79
Dividend TTM	-	Quick Ratio	3.04	Sales past 5Y	25.79%	Gross Margin	99.71%	52W Low	51.26%	ATR (14)	0.08
Dividend Ex-Date	Jun 12, 2009	Current Ratio	3.04	EPS Y/Y TTM	44.73%	Oper. Margin	-14.74%	RSI (14)	45.03	Volatility	8.86% 9.07%
Employees	44	Debt/Eq	0.02	Sales Y/Y TTM	7.70%	Profit Margin	-10.05%	Recom	1.67	Target Price	4.33
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	99.81%	Payout	-	Rel Volume	1.84	Prev Close	0.68
Sales Surprise	5.29%	EPS Surprise	-100.00%	Sales Q/Q	37.10%	Earnings	Nov 13 AMC	Avg Volume	170.05K	Price	0.73
SMA20	-0.00%	SMA50	-16.36%	SMA200	-40.97%	Trades		Volume	312,959	Change	7.88%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-29-21	Resumed	Stifel	Buy	$12
Sep-15-21	Initiated	Cantor Fitzgerald	Overweight	$14
Jul-14-20	Reiterated	H.C. Wainwright	Buy	$14 → $24
Jul-10-20	Resumed	Stifel	Buy	$22 → $10
Feb-22-19	Initiated	SVB Leerink	Outperform	$16

Nov-13-24 04:01PM	Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates (Business Wire) -8.18% -12.33%
08:00AM	Equillium to Present at the Stifel Healthcare Conference (Business Wire)
Nov-12-24 08:00AM	Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer (Business Wire) +13.24%
Nov-06-24 10:00AM	Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth (Zacks)
Oct-31-24 07:00AM	Equillium Maintains Rights to Itolizumab Following Ono Partnership (Business Wire) -37.61%
08:00AM	Loading…
Oct-07-24 08:00AM	Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (Business Wire) +8.00%
Sep-17-24 11:54AM	Equillium collaborates with Vivtex for oral formulation of autoimmune therapy (Pharmaceutical Technology)
Sep-10-24 08:00AM	Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit (Business Wire)
Sep-04-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-28-24 08:00AM	Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference (Business Wire)
Aug-08-24 05:35PM	Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights (Business Wire)
Aug-06-24 08:00AM	Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease (Business Wire) +14.85%
Jul-18-24 01:57PM	Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance (Business Wire)
Jul-02-24 08:00AM	Equillium to Participate in Upcoming Investor Conferences (Business Wire)
08:00AM	Loading…
Jun-12-24 08:00AM	Equillium to be included in the Russell Microcap Index (Business Wire)
Jun-05-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -19.08%
Jun-04-24 08:00AM	Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata (Business Wire) -27.89%
May-29-24 08:00AM	Equillium to Present at the Jefferies Global Healthcare Conference (Business Wire) -5.48%
May-14-24 08:00AM	Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease (Business Wire)
May-09-24 10:56PM	EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.88% -15.00%
05:35PM	Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights (Business Wire)
May-07-24 08:00AM	Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists (Business Wire)
Apr-03-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.88%
Apr-01-24 10:15AM	Equillium's lupus drug improves kidney biomarker, teeing up opt-in decision from Ono (FierceBiotech.com) -8.66%
08:00AM	Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis (Business Wire)
Mar-25-24 09:53PM	EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -13.48% -15.57%
05:10PM	Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights (Business Wire)
08:00AM	Loading…
Mar-22-24 08:00AM	Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference (Business Wire)
Jan-29-24 04:07AM	15 Cash-Rich Penny Stocks Hedge Funds Are Buying (Insider Monkey)
Dec-21-23 09:52AM	Equillium swaps multi-cytokine inhibitor for oral option after underwhelming phase 2 data (FierceBiotech.com) -9.57%
08:00AM	Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease (Business Wire)
Nov-20-23 11:23AM	EQ Bank Card launches in Québec as Carte Banque EQ (PR Newswire)
Nov-13-23 09:00AM	Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology (Business Wire)
Nov-08-23 04:01PM	Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (Business Wire)
Nov-06-23 08:00AM	Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology (Business Wire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) -7.52%
Oct-19-23 08:00AM	Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology (Business Wire)
Oct-16-23 08:00AM	Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium (Business Wire) +6.66%
Oct-03-23 08:00AM	Equillium to Host Analyst & Investor Day (Business Wire)
Oct-02-23 08:00AM	Equillium to Present at the JonesTrading 2023 Healthcare Summit (Business Wire)
Sep-20-23 08:00AM	Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences (Business Wire)
Aug-30-23 08:00AM	Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference (Business Wire)
Aug-12-23 08:05AM	Equillium, Inc. (NASDAQ:EQ) Just Reported, And Analysts Assigned A US$6.06 Price Target (Simply Wall St.)
Aug-09-23 05:30PM	Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (Business Wire)
Aug-02-23 04:00PM	Equillium Announces $7.5 Million Share Repurchase Program (Business Wire)
Jun-01-23 08:00AM	Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences (Business Wire)
May-15-23 08:00AM	Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists (Business Wire) +16.84%
May-11-23 05:25PM	Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates (Business Wire)
May-03-23 06:14AM	News Flash: Analysts Just Made A Meaningful Upgrade To Their Equillium, Inc. (NASDAQ:EQ) Forecasts (Simply Wall St.)
Apr-24-23 08:00AM	Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation (Business Wire)
Mar-23-23 04:01PM	Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates (Business Wire) +11.54%
Mar-22-23 08:00AM	Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference (Business Wire)
Feb-17-23 08:00AM	Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR (Business Wire)
Feb-07-23 08:00AM	Equillium to Present at the SVB Securities Annual Global Healthcare Conference (Business Wire)
Jan-13-23 08:00AM	Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Business Wire) -6.78%
Dec-23-22 04:01PM	Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement (Business Wire) -5.62%
Dec-16-22 08:00AM	Equilliums Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis (Business Wire)
Dec-06-22 12:17PM	Autoimmune Biotech Scores $26M Payment, Up To $139M To Advance Phase 3 Research (Benzinga)
07:00AM	Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab (Business Wire)
Nov-14-22 04:01PM	Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates (Business Wire) +5.35%
08:00AM	Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022 (Business Wire)
Nov-10-22 08:00AM	Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata (Business Wire)
Nov-08-22 08:00AM	Equillium to Present at Two Upcoming Investor Conferences (Business Wire)
Nov-03-22 08:00AM	Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit (Business Wire)
Nov-02-22 08:00AM	Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease (Business Wire)
Oct-26-22 08:00AM	Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference (Business Wire)
Sep-27-22 08:15AM	Equillium's stock is up 12% after sharing early data about its investigational lupus treatment (MarketWatch) +22.80%
08:04AM	Equillium Shares Ride Higher After Positive Data From Lead Asset In Kidney Inflammation (Benzinga)
07:00AM	Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis (Business Wire)
Sep-15-22 08:00AM	Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022 (Business Wire)
Sep-07-22 05:58AM	Equillium Buys Inflammatory Bowel Disease Player In All-Stock Deal (Benzinga) -11.72%
Sep-06-22 04:00PM	Equillium to Acquire Metacrine in All-Stock Transaction (Business Wire)
Aug-31-22 08:00AM	Equillium to Present at Two Upcoming Investor Conferences (Business Wire)
Aug-18-22 07:48AM	What Kind Of Shareholders Hold The Majority In Equillium, Inc.'s (NASDAQ:EQ) Shares? (Simply Wall St.) -14.01%
Aug-15-22 04:01PM	Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates (Business Wire)
Jul-28-22 08:00AM	Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit (Business Wire)
Jun-14-22 02:09PM	Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock (Benzinga)
May-17-22 08:00AM	Equillium to Present at Two Upcoming Investor Conferences (Business Wire) +10.71%
May-12-22 04:01PM	Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates (Business Wire)
08:00AM	Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association (Business Wire)
May-09-22 08:00AM	Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists (Business Wire) -5.93%
Apr-25-22 08:00AM	Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR (Business Wire)
Apr-04-22 08:00AM	Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology (Business Wire)
Mar-29-22 10:00AM	Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ) (Zacks)
Mar-28-22 12:00PM	EQ Inc. to Present at Canaccord Genuity Canadian Technology Conference (ACCESSWIRE) -8.28%
Mar-24-22 08:00AM	EQ Works and Tapad Initiative Creates Canada's Largest Device Identity Graph (ACCESSWIRE)
Mar-23-22 04:01PM	Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates (Business Wire)
01:42PM	Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation (Business Wire)
Mar-04-22 08:00AM	Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease (Business Wire)
Mar-01-22 08:00AM	Equillium Announces Appointment of Barbara Troupin to Board of Directors (Business Wire)
Feb-16-22 11:22AM	Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition (Benzinga)
07:00AM	Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates (Business Wire)
Feb-15-22 08:00AM	Equillium Provides Timing Update on Conference Presentations (Business Wire) +6.38%
Feb-09-22 08:00AM	Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference (Business Wire)
Feb-02-22 06:46AM	What Type Of Shareholders Own The Most Number of Equillium, Inc. (NASDAQ:EQ) Shares? (Simply Wall St.)

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Keyes Jason A	Chief Financial Officer	Nov 14 '24	Sale	0.70	10,000	7,000	47,720	Nov 15 06:23 PM
THE KEYES TRUST U/A DTD 09/10/	Officer	Nov 14 '24	Proposed Sale	0.78	20,000	15,608		Nov 14 04:19 PM
Zedelmayer Christine	Officer	Oct 28 '24	Proposed Sale	1.25	15,000	18,750		Oct 31 12:19 PM
Zedelmayer Christine	Sr. Vice President and COO	Oct 28 '24	Sale	1.25	15,000	18,750	135,246	Oct 30 08:59 PM
Tom Penny	Principal Accounting Officer	Oct 28 '24	Sale	1.25	2,835	3,544	6,533	Oct 29 04:15 PM
Tom Penny	Principal Accounting Officer	Oct 25 '24	Sale	1.25	683	854	9,368	Oct 29 04:15 PM
Keyes Jason A	Chief Financial Officer	Sep 26 '24	Sale	0.81	10,000	8,100	57,720	Sep 27 07:38 PM
Tom Penny	Principal Accounting Officer	Sep 16 '24	Sale	0.85	38,806	32,985	10,051	Sep 17 06:14 PM
Keyes Jason A	Chief Financial Officer	Jul 16 '24	Sale	0.87	10,000	8,700	67,720	Jul 18 05:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EQ

Equillium Inc

Upgrade your FINVIZ experience